The immunodiagnostics market is a rapidly evolving segment of the global healthcare diagnostics industry, driven by technological innovations, increasing demand for early disease detection, and the growing prevalence of chronic and infectious diseases. In 2024, the market was valued at USD 22.20 billion, and it is poised to expand at a CAGR of 7% from 2025 to 2032, reaching USD 38.06 billion by 2032. North America led the global market with a 37.11% share in 2024, owing to its advanced healthcare infrastructure and high R&D spending. The market is witnessing robust developments, with major players continually innovating to meet the rising demand for faster, accurate, and point-of-care diagnostic tools.

Market Size and Growth Forecast

The global immunodiagnostics market was valued at USD 22.20 billion in 2024, and it is projected to reach USD 23.52 billion in 2025, eventually climbing to USD 38.06 billion by 2032. This steady growth reflects the increasing application of immunodiagnostic tools in disease diagnosis, including:

The 7% CAGR (2025–2032) is fueled by advancements in biosensors, microfluidics, and AI integration in diagnostic tools, enabling higher accuracy and faster turnaround times.

Market Drivers

  1. Rising Prevalence of Chronic & Infectious DiseasesThe surge in lifestyle diseases and recurring outbreaks of infectious diseases worldwide has boosted the demand for early and precise diagnostics.
  2. Technological AdvancementsInnovations like automated immunoassay systems, multiplex assays, and AI-based diagnostic platforms are enhancing the accuracy and efficiency of immunodiagnostic tests.
  3. Growing Geriatric PopulationAging populations are more susceptible to various diseases, necessitating reliable diagnostic techniques, especially in developed regions.
  4. **Increased Point-of-Care Testing (POCT)**The push toward decentralized healthcare and rapid diagnostics has increased the adoption of immunodiagnostic POCT kits.
  5. Expanding Healthcare Infrastructure in Emerging MarketsAsia-Pacific and Latin America are witnessing improvements in healthcare access and diagnostics penetration, offering new growth opportunities.

Regional Insights

North America – Leading the Market

In 2024, North America dominated the immunodiagnostics market with a 37.11% share, primarily due to: